June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Novel corticosteroids with inhibitory activity against ROCK reach target ocular tissues and reduce inflammation in EIU
Author Affiliations & Notes
  • Maria V Zaretskaia
    Research & Development, Aerie Pharmaceuticals, Durham, North Carolina, United States
  • Kevin Carbajal
    Research & Development, Aerie Pharmaceuticals, Durham, North Carolina, United States
  • Cyndi Lichorowic
    Research & Development, Aerie Pharmaceuticals, Durham, North Carolina, United States
  • Jill M. Sturdivant
    Research & Development, Aerie Pharmaceuticals, Durham, North Carolina, United States
  • Eric C Carlson
    Research & Development, Aerie Pharmaceuticals, Durham, North Carolina, United States
  • Monica Germann
    Research & Development, Aerie Pharmaceuticals, Durham, North Carolina, United States
  • Karen Crews
    Research & Development, Aerie Pharmaceuticals, Durham, North Carolina, United States
  • Meredith Weksler
    Research & Development, Aerie Pharmaceuticals, Durham, North Carolina, United States
  • Alan McDougal
    Research & Development, Aerie Pharmaceuticals, Durham, North Carolina, United States
  • Mitchell A. deLong
    Research & Development, Aerie Pharmaceuticals, Durham, North Carolina, United States
  • Casey Kopczynski
    Research & Development, Aerie Pharmaceuticals, Durham, North Carolina, United States
  • Cheng-Wen Lin
    Research & Development, Aerie Pharmaceuticals, Durham, North Carolina, United States
  • Footnotes
    Commercial Relationships   Maria Zaretskaia, Aerie Pharmaceuticals (E); Kevin Carbajal, Aerie Pharmaceuticals (E); Cyndi Lichorowic, Aerie Pharmaceuticals (E); Jill Sturdivant, Aerie Pharmaceuticals (E); Eric Carlson, Aerie Pharmaceuticals (E); Monica Germann, Aerie Pharmaceuticals (E); Karen Crews, Aerie Pharmaceuticals (E); Meredith Weksler, Aerie Pharmaceuticals (E); Alan McDougal, Aerie Pharmaceuticals (E); Mitchell deLong, Aerie Pharmaceuticals (E); Casey Kopczynski, Aerie Pharmaceuticals (E); Cheng-Wen Lin, Aerie Pharmaceuticals (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2983. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maria V Zaretskaia, Kevin Carbajal, Cyndi Lichorowic, Jill M. Sturdivant, Eric C Carlson, Monica Germann, Karen Crews, Meredith Weksler, Alan McDougal, Mitchell A. deLong, Casey Kopczynski, Cheng-Wen Lin; Novel corticosteroids with inhibitory activity against ROCK reach target ocular tissues and reduce inflammation in EIU. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2983.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The anti-inflammatory efficacy of corticosteroids is unmatched and widely utilized in ocular indications. However, risks to steroid use are significant and include steroid-induced ocular hypertension/glaucoma, which is thought to develop as extracellular matrix proteins accumulate and impair proper function of the trabecular meshwork (TM). Rho kinase (ROCK) inhibition has been shown to attenuate steroid-induced collagen and fibronectin deposition in cultured TM cells. Furthermore, ROCK inhibition has been shown to lower IOP by increasing aqueous outflow through the TM. Inhibition of ROCK in conjunction with steroid use for ocular inflammatory conditions may provide a strategy to decrease the risk for steroid-induced glaucoma. We describe the generation of novel corticosteroids covalently linked to ROCK inhibitor compounds and report their tissue distribution following topical dosing as well as their anti-inflammatory efficacy in the mouse endotoxin-induced uveitis (EIU) model.

Methods : Over 50 novel compounds containing a steroid linked to a ROCK inhibitor were synthesized. Dexamethasone, prednisolone, fluocinolone, and triamcinolone were linked to various ROCK inhibitors including the active metabolite of netarsudil, AR-13503. Ocular tissue distribution following topical administration was assessed by mass spectrometry. Anti-inflammatory efficacy was determined in the EIU model following topical instillation.

Results : Following topical dosing with the ROCK-steroids, the steroid and the ROCK-inhibitor metabolites are found in various ocular tissues. Low doses of these novel compounds reduce inflammation in EIU to levels comparable to clinically relevant treatments today.

Conclusions : Covalently linked ROCK-steroid compounds retain their anti-inflammatory efficacy. The potential for these compounds to provide lower risk profiles than conventional corticosteroids deserves further investigation.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×